Effective January 1, 2017 - New permanent J-code for ONIVYDE: J9205, injection, irinotecan liposome, 1 mg This information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.

FOR US HEALTHCARE PROFESSIONALS ONLY Call Us at (844) 441-MACK (6225)

HIT
PANCREATIC
CANCER
HEAD ON

ONIVYDE®

(irinotecan liposome injection)

The first and only therapy FDA-approved
in combination for patients with metastatic pancreatic cancer after disease progression following gemcitabine-based therapy1,2

  • EXPERT VIDEOS &
    RESOURCES

    Two clinical experts review the results of the NAPOLI-1 study

  • one

    CELEBRATING 1 YEAR

    Initial FDA approval on October 22, 2015

  • PROVYDE® ONIVYDE®
    ACCESS SERVICES

    Learn more about services and support for accessing ONIVYDE

INDICATION AND IMPORTANT SAFETY INFORMATION

**National Comprehensive Cancer Network® (NCCN®).

References: 1. ONIVYDE [package insert]. Cambridge, MA. Merrimack Pharmaceuticals, Inc.; October 2015. 2. Data on file. Merrimack Pharmaceuticals, Inc.; Cambridge, MA.

EXPAND

INDICATION AND IMPORTANT
SAFETY INFORMATION